Sentences with phrase «many lung cancer patients»

That leaves Merck largely free of competitors in the near - term in its quest to become a go - to, first - line option for lung cancer patients in combination with chemotherapy (Merck recently surprised investors with an early FDA filing for that combination).

Immune cells modified by CRISPR - Cas9 were inserted into a lung cancer patient at the West China Hospital in Chengdu in the hopes that they'll be able to fight tumors, and 10 people total will receive injections of CRISPR re-engineered cells in order to assess the method's safety.

That's not just because of Opdivo's failure — last month, Keytruda was shown to be better than standard chemotherapy in untreated advanced lung cancer patients with high levels of the PD - L1 protein, both stopping cancer progression and extending patients» lives.

Researchers from the Sichuan University in Chengdu inserted the re-engineered cells into a lung cancer patient participating in a clinical trial at the West China Hospital on October 28th, according to Nature.

Merck's cancer immunotherapy Keytruda is one of the pharma giant's rising stars, especially in the wake of evidence that the therapy had a survival benefit over standard chemotherapy in advanced lung cancer patients.

The drug had $ 942 million in global 2015 sales (versus $ 566 million for Keytruda) and, according to the company, has been prescribed to 60 % of new lung cancer patients.

The company actually beat Wall Street profit estimates largely thanks to its superstar cancer immunotherapy drug Keytruda, which has been shown to best chemotherapy in helping lung cancer patients live longer and given Merck a leg up over rivals like Bristol - Myers Squibb's immune therapy Opdivo.

Related Articles: Merck's Keytruda held back by docs who don't want to wait for diagnostics Bristol's Opdivo - Yervoy combo ups response rates in first - line lung cancer patients Roche's Tecentriq bursts onto immuno - oncology scene, with Merck and BMS in its sights Bristol - Myers» new Opdivo ad touts biomarker advantage over Merck's Keytruda Merck's Keytruda lines up its survival data for stepped - up battle with BMS» Opdivo

The PD - 1 checkpoint inhibitor Keytruda hit its goals in a new trial in previously untreated non-small cell lung cancer patients, beating chemo at staving off cancer progression and extending patients» lives.

Meanwhile, Bristol - Myers rolled out data from a new analysis comparing Opdivo and its fellow BMS immunotherapy Yervoy against Opdivo alone in previously untreated lung cancer patients.

In a mid-stage trial, 16 of 37 lung cancer patients given a placebo ahead of standard chemo wound up hospitalized with severely low white blood cell counts.

«What is particularly encouraging is that we are now able to select, based on features in the tumor, approximately a quarter of advanced lung cancer patients who can receive immunotherapy as their initial treatment.

Additionally, lung cancer patients who have high levels of YAP1 in their tumors are more likely to have a poorer prognosis than patients with low levels of YAP1.

A lung cancer specialist, Wrangle said 75 percent of lung cancer patients unfortunately are diagnosed at an incurable stage.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

Both of the researchers, who are in their early forties, said they were motivated by the need to give lung cancer patients better options.

For example, lung cancer patients who were injected with killed M. vaccae reported better quality of life and less nausea and pain.

Dr. Glen Weiss, M.D., M.B.A., is the first author of the study abstract: Phase Ib / II Study of Pembrolizumab plus Chemotherapy in Advanced Cancer: Results of lung cancer patients receiving (at least) 1 prior line of therapy.

Unfortunately, the treatment had little effect on the survival of the terminally ill lung cancer patients in the first trial.

Findings were presented at the WCLC are based on the updated results of 12 lung cancer patients enrolled in the clinical trial with pembro and irinotecan or gemcitabine with or without vinorelbine or docetaxel.

«Link between inherited genetic variations, outcomes of non-small cell lung cancer patients discovered.»

The researchers combined data from lung cancer patients in The Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) with claims data from the Centers for Medicare & Medicaid Services (CMS).

The team studied a lung cancer drug called erlotinib which can be used to treat between 10 and 30 per cent of lung cancer patients.

«Blocking both of these proteins could be a treatment that is beneficial for the majority of lung cancer patients,» said Dr. Habib, Associate Professor of Neurology and Neurotherapeutics with UT Southwestern's Peter O'Donnell Jr..

«We urgently need new treatments for lung cancer patients, and this research suggests we can boost the effectiveness of an existing drug, rather than switch to another new expensive treatment.

«Process to help personalize treatment for lung cancer patients developed.»

Key findings in this study show that 5 - year survival for older lung cancer surgery patients is favorable; surgeons will be able to better individualize care for older lung cancer patients based on newly and uniquely linked data, and the prevalence of lung cancer is expected to increase as the population continues to age.

The clinical trial being planned will test the treatment in both lung cancer patients and those with glioblastomas.

Recent findings suggest a novel positron emission tomography (PET) imaging approach determining epidermal growth factor receptor (EGFR) mutation status for improved lung cancer patient management.

«Although some non-small cell lung cancer patients have increased benefit of targeted therapy or immunotherapy instead of chemotherapy, for some groups of patients with NSNSCLC, chemotherapy has been the standard treatment for more than 30 years,» Gandhi notes.

«There is growing evidence that such targeted therapies can offer greater hope to lung cancer patients.

An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.

To test the notion, the scientists examined DNA from four lung cancer patients, isolating fragments that were 20 - 50 base pairs shorter than the total average size in circulation.

«If you look at a set of lung cancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hospital.

«First - line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»

The study used samples from lung cancer patients with brain metastases.

Published in the Journal of Clinical Investigation, the study collected metabolic data directly from more than 120 human lung cancer patients.

As a result, this group succeeded in isolating ORs which respond to three types of volatile organic compounds (2 - pentanone, pyridine, 2 - butanone) respectively in urine samples from lung cancer patients.

«Rare mutation may extend survival in lung cancer patients with brain metastases.»

A recent study in Manchester has found that a procedure to take tissue samples from lung cancer patients can be used safely in the elderly — allowing doctors to make a more accurate diagnosis and to choose appropriate treatment.

«The prevalence of comorbidities is higher in older lung cancer patients than patients who are younger,» said K.M. Monirul Islam, M.D., Ph.D., an assistant professor in the department of epidemiology at the University of Nebraska Medical Center College of Public Health.

«As the population of the United States ages, there will be a higher number of lung cancer patients with comorbidities at diagnosis.»

Half of all lung cancer patients are over 70 years old when first diagnosed, but studies have shown that these older patients are less likely to receive an accurate diagnosis.

One early project was to help Genoptix — a Novartis daughter - company acquired in 2011 and located in Carlsbad, California — to commercialize a diagnostic test for lung cancer patients.

Testing for the EGFR mutation and ALK rearrangements and the use of targeted therapies have given lung cancer patients the chance for survival, along with improved quality of life and time with loved ones.

Their initial experiments found increased bone activity in two mouse models of a common form of lung cancer and in 70 lung cancer patients, even in absence of bone metastasis.

The same benefits of increased activity observed in lung cancer patients, especially improved symptoms and quality of life, appear to apply to lung cancer survivors as well.

Chronically - ill cancer patients have different exercise limitations than their healthy counterparts and other concurrent diseases and high symptom burden add challenges in how best to study and implement physical activity programs in lung cancer patients.

The authors found that most lung cancer patients (regardless of stage) want physical activity advice directly from a physician at a cancer center before cancer treatment and exercise guidance may increase compliance with a dedicated program.

However, «there are still large gaps in the published literature to be addressed and these could be filled with large definitive prospective trials that evaluate the benefit of exercise in lung cancer patients.»